{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:08:33Z","timestamp":1793200113164,"version":"4.5.0"},"reference-count":42,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alpe d\u2019HuZes\/Dutch Cancer Society (KWF) fund","award":["14932"],"award-info":[{"award-number":["14932"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>For patients with perihilar cholangiocarcinoma (pCCA), surgical resection remains the sole treatment modality that can potentially result in cure. Unfortunately, the majority of patients present with unresectable tumours or are excluded from surgical treatment due to complications like cholangitis affecting their performance status. In the Netherlands, recommended first-line treatment for patients with unresectable pCCA is palliative chemotherapy with gemcitabine and cisplatin. This regimen yields an estimated median overall survival (OS) of 11.7\u201315.2 months, highlighting the urgent need for novel treatment options. The STRONG I trial, a phase I study in patients with unresectable pCCA, was completed in 2020. Its aim was to assess the feasibility and toxicity profile of adding stereotactic body radiation therapy (SBRT) to chemotherapy. SBRT, delivered in 15 fractions of 4.0 Gray (Gy), was considered to be feasible and safe, with no dose-limiting toxicity being observed. The 1-year local tumour control rate was 80% and the 1-year OS rate 100%, with maintenance of quality of life (QoL). These results encouraged us to initiate the STRONG II trial, aiming to investigate the efficacy of adding SBRT to chemotherapy in a larger patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>STRONG II is a single-arm, multicentre phase II study. Patients with non-metastatic unresectable pCCA (T1-4, N0-2) are eligible. A total of 30 patients will be enrolled in six academic centres in the Netherlands and two in Belgium. SBRT will be delivered in 15 fractions of 4.0\u20134.5\u2009Gy. The primary endpoint is local tumour control, defined by Response Evaluation Criteria in Solid Tumours (RECIST) V.1.1. Secondary endpoints include toxicity, biliary stent-related events, progression-free survival, OS and QoL using the EuroQoL five-dimensional, five-level (EQ-5D-5L) questionnaire, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) and the EORTC Biliary Module (QLQ-BIL21). In addition, we will explore the predictive value of the peripheral immunological status (immune-related proteins and serum functional immunological status assay) and its dynamics in determining survival outcomes. For this explorative translational study, two blood samples will be collected, one before the start of chemotherapy and another after completing chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Approval of the study was obtained on 5 June 2024 by the Medical Ethics Review Committee of Erasmus Medical Center Rotterdam, the Netherlands (ID: NL86210.078.24). The anticipated time frame for patient enrolment is July 2024 to December 2027. The main study findings will be published in peer-reviewed medical journals, and presented at national and international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06493734\">NCT06493734<\/jats:ext-link>\n                      (ClinicalTrials.gov).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-097545","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:11:14Z","timestamp":1752657074000},"page":"e097545","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma \u2013 a single-arm multicentre phase II study"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06493734","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06493734","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4197-4951","authenticated-orcid":false,"given":"Suus Y","family":"van Loosbroek","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike T W","family":"Milder","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"de Ruysscher","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"},{"name":"Department of Radiation Oncology (Maastro), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne D W","family":"Vaes","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (Maastro), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"den Toom","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Willemssen","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry","family":"Eskens","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein Y V","family":"Homs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[{"name":"Department of Surgery, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydi M J W","family":"van Driel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Seppenwoolde","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"van Werkhoven","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Intven","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Haj Mohammad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"de Bruijne","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Versteijne","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M","family":"Bruynzeel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek","family":"Brandts","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris I","family":"Erdmann","sequence":"additional","affiliation":[{"name":"Department of Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Westdorp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e8tra M","family":"Braam","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T T L","family":"Tjwa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Bouchart","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, H\u00f4pital Universitaire de Bruxelles (H.U.B.) - Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles (ULB), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Demols","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Digestive Oncology, H\u00f4pital Erasme and Institut Jules Bordet HUB, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akos","family":"Gulyban","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, H\u00f4pital Universitaire de Bruxelles (H.U.B.) - Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles (ULB), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Buijsen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (Maastro), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dewulf","sequence":"additional","affiliation":[{"name":"Department of Surgery, Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Joye","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iridium Netwerk, Wilrijk \u2013 Antwerp, Belgium"},{"name":"University of Antwerp, Centre for Oncological Research (CORE)-IPPON, Faculty of Medicine and Health Sciences, Wilrijk \u2013 Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timon","family":"Vandamme","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital Antwerp, Edegem, Belgium"},{"name":"Center for Oncological Research, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Vonghia","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk Jan","family":"de Groot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margriet","family":"Dieters","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred J F","family":"Ubbels","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik J H","family":"Hoogwater","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Heijmen","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"PH.D.","given":"Alejandra","family":"M\u00e9ndez Romero","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2025121509221742000_15.7.e097545.1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clon.2014.05.016","article-title":"The Role of Radiotherapy and Chemoradiation in the Management of Primary Liver Tumours","volume":"26","author":"Aitken","year":"2014","journal-title":"Clin Oncol"},{"key":"2025121509221742000_15.7.e097545.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z"},{"key":"2025121509221742000_15.7.e097545.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.09.017"},{"key":"2025121509221742000_15.7.e097545.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091776","article-title":"The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review","volume":"16","author":"Verma","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025121509221742000_15.7.e097545.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"2025121509221742000_15.7.e097545.6","first-page":"155","article-title":"Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis","volume":"4","author":"Eckmann","year":"2011","journal-title":"Gastrointest Cancer Res"},{"key":"2025121509221742000_15.7.e097545.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163991","article-title":"Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study","volume":"13","author":"Baak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025121509221742000_15.7.e097545.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3778"},{"key":"2025121509221742000_15.7.e097545.9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121509221742000_15.7.e097545.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"2025121509221742000_15.7.e097545.11","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0692-z","article-title":"Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade","volume":"7","author":"Liu","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025121509221742000_15.7.e097545.12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/15384047.2020.1834792","article-title":"Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases","volume":"22","author":"Zhao","year":"2021","journal-title":"Cancer Biol Ther"},{"key":"2025121509221742000_15.7.e097545.13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246259","article-title":"Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study","volume":"13","author":"Vaes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025121509221742000_15.7.e097545.14","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.3748\/wjg.v22.i26.6065","article-title":"Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy","volume":"22","author":"Lamarca","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2025121509221742000_15.7.e097545.15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003609","article-title":"Peripherally-driven myeloid NFkB and IFN\/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer","volume":"9","author":"Sprooten","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025121509221742000_15.7.e097545.16","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/hep.25629","article-title":"Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma","volume":"56","author":"Murad","year":"2012","journal-title":"Hepatology"},{"key":"2025121509221742000_15.7.e097545.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2013.06.004"},{"key":"2025121509221742000_15.7.e097545.18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1114737","article-title":"Inter- and intrafraction dose variations in robotic stereotactic body radiation therapy (SBRT) for perihilar cholangiocarcinoma in the prospective phase I STRONG trial","volume":"13","author":"Paronetto","year":"2023","journal-title":"Front Oncol"},{"key":"2025121509221742000_15.7.e097545.19","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000682"},{"key":"2025121509221742000_15.7.e097545.20","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2024.42.16_suppl.4006","article-title":"Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial","volume":"42","author":"Hawkins","year":"2024","journal-title":"JCO"},{"key":"2025121509221742000_15.7.e097545.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.11.004"},{"key":"2025121509221742000_15.7.e097545.22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.adro.2019.08.003","article-title":"Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control With Elective Nodal Irradiation","volume":"5","author":"Kozak","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"2025121509221742000_15.7.e097545.23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2011.05.016","article-title":"Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience","volume":"99","author":"Polistina","year":"2011","journal-title":"Radiother Oncol"},{"key":"2025121509221742000_15.7.e097545.24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2010.03.013","article-title":"Stereotactic fractionated radiotherapy for Klatskin tumours","volume":"95","author":"Momm","year":"2010","journal-title":"Radiother Oncol"},{"key":"2025121509221742000_15.7.e097545.25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121509221742000_15.7.e097545.26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1040673","article-title":"Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac","volume":"13","author":"Eijkelenkamp","year":"2023","journal-title":"Front Oncol"},{"key":"2025121509221742000_15.7.e097545.27","doi-asserted-by":"crossref","first-page":"110347","DOI":"10.1016\/j.radonc.2024.110347","article-title":"Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer \u2013 A phase II study","volume":"197","author":"Weisz Ejlsmark","year":"2024","journal-title":"Radiother Oncol"},{"key":"2025121509221742000_15.7.e097545.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.phro.2023.100434","article-title":"Feasibility of online radial magnetic resonance imaging for adaptive radiotherapy of pancreatic tumors","volume":"26","author":"Grimbergen","year":"2023","journal-title":"Phys Imaging Radiat Oncol"},{"key":"2025121509221742000_15.7.e097545.29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.radonc.2022.08.026","article-title":"Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer","volume":"175","author":"Schiff","year":"2022","journal-title":"Radiother Oncol"},{"key":"2025121509221742000_15.7.e097545.30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.meddos.2021.06.001","article-title":"Magnetic resonance image-guided hypofractionated ablative radiation therapy for extrahepatic cholangiocarcinoma: Plan adaptation in changing anatomy","volume":"46","author":"Egriboyun","year":"2021","journal-title":"Med Dosim"},{"key":"2025121509221742000_15.7.e097545.31","article-title":"Clinical outcomes of patients with unresectable primary liver cancer treated with MR-guided stereotactic body radiation Therapy: A Six-Year experience","volume":"41","author":"Chin","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"2025121509221742000_15.7.e097545.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"2025121509221742000_15.7.e097545.33","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN guidelines\u00ae Insights: biliary tract cancers, version 2.2023: featured updates to the NCCN guidelines","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2025121509221742000_15.7.e097545.34","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00368","article-title":"Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report","volume":"7","author":"Liu","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2025121509221742000_15.7.e097545.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-024-03381-4","article-title":"Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"Zhu","year":"2024","journal-title":"BMC Med"},{"key":"2025121509221742000_15.7.e097545.36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ijrobp.2022.03.019","article-title":"The Combination of Radiation Therapy and Immunotherapy Is Effective and Well-Tolerated for Unresectable Biliary Tract Cancer","volume":"113","author":"Chen","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121509221742000_15.7.e097545.37","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.hpb.2024.03.138","article-title":"Primary percutaneous stenting above the ampulla versus endoscopic drainage for unresectable malignant hilar biliary obstruction (TESLA RCT): a multicenter randomized controlled trial - clinical trials in progress","volume":"26","author":"Rousian","year":"2024","journal-title":"HPB (Oxford)"},{"key":"2025121509221742000_15.7.e097545.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.01.002"},{"key":"2025121509221742000_15.7.e097545.39","doi-asserted-by":"publisher","DOI":"10.1080\/02841860600936369"},{"key":"2025121509221742000_15.7.e097545.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.009"},{"key":"2025121509221742000_15.7.e097545.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.05.071"},{"key":"2025121509221742000_15.7.e097545.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.07.1977"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-097545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:22:28Z","timestamp":1765819348000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-097545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2024-097545"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097545","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}